Shire blasts Roche over its 'misleading' case for trailblazing hemophilia drug emicizumab, scoring injunction
Over the past year, Shire $SHPG has seen its shares buffeted repeatedly as Roche moved steadily ahead with its late-stage program for its closely-watched hemophilia A drug emicizumab (ACE910). Now it’s fighting back, taking Roche to court over the weekend, ahead of any regulatory decision for a series of what it claims are damaging and misleading comments about the drug’s relative safety and efficacy. But Roche immediately fired back Monday morning with more Phase III data, with no sign that Shire’s assault had influenced its latest update.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.